A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4⁺ T cellsDE BOER, Alberdina W; MARKOWITZ, Norman; LANE, H. Clifford et al.Clinical immunology (Orlando, Fla. Print). 2003, Vol 106, Num 3, pp 188-196, issn 1521-6616, 9 p.Article

Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental IndicationsKAISER, Lee D; MELEMED, Allen S; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2010, Vol 28, Num 34, pp 5046-5053, issn 0732-183X, 8 p.Article